Polypharmacy in the treatment of schizophrenia;Polypharmazie in der behandlung der schizophrenie

Fortschritte der Neurologie Psychiatrie

Volumn 74, Issue 7, 2006, Pages 377-391

  Messer, Thomas ^a   Tiltscher, C ^a   Schmauss, M ^a  

^a Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; COMORBIDITY; DEPRESSION; DRUG COST; EDUCATION; HOSPITAL PATIENT; HUMAN; MONOTHERAPY; OUTPATIENT; PATIENT COMPLIANCE; POLYPHARMACY; PSYCHOPHARMACOLOGY; RISK FACTOR; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; SCHIZOPHRENIA;

EID: 33746225541     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-915576     Document Type: Article

References (223)

1. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106 (5): 323-330
2. Naber D. Atypical antipsychotics. Nervenarzt 2000; 71 (5): 327-328
3. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret? J Clin Psychiatry 1999; 60 (7): 425-426
4. Linden M, Scheel T, Xaver EF. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Hum Psychopharmacol 2004; 19 (2): 111-119
5. Tapp A, Wood AE, Secrest L et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv 2003; 54 (1): 55-59
6. Keks NA, Altson K, Hope J et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N ZJ Psychiatry 1999; 33 (6): 896-901
7. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28 (1): 75-84
8. Meltzer H, Kostakoglu A. Combining Antipsychotics: Is there Evidence for Efficacy? Psychiatric Times, 2004; XVII (9)
9. Brunot A, Lachaux B, Sontag H et al. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia]. Encephale 2002; 28 (2): 129-138
10. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors. Med Care 2001; 39 (9): 923-933
11. Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry 1999; 60 Suppl 10: 20-30
12. Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. Ann Pharmacother 2003; 37 (7-8): 951-955
13. Sim K, Su A, Fujii S et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004; 58 (2): 178-183
14. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 Suppl: S35-S40
15. Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (2): 361-369
16. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987; 150: 501-504
17. Oepen G. Polypharmacy in Schizophrenia. In: Ghaemi SN (ed.). Polypharmacy in Psychiatry. Dekker, 2002
18. Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002; 28 (1): 17-29
19. Rittmannsberger H, Meise U, Schauflinger K et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999; 14 (1): 33-40
20. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003; 64 (9): 984-989
21. Lerner V, Libov I, Kotler M, Strous RD. Combination of "atypical" antipsychotic medication in the management of treatment-resistant schizophrenia and schizoaffective disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (1): 89-98
22. th Annual Meeting APA, New York, 2004
23. th Annual Meeting APA, Atlanta, 2005
24. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001; 46 (4): 334-339
25. Procyshyn RM, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry 2004; 37 (1): 12-17
26. Godleski LS, Kerler R, Barber JW et al. Multiple versus single antipsychotic drug treatment in chronic psychosis. J Nerv Ment Dis 1989; 177 (11): 686-689
27. Huttunen MO, Tuhkanen H, Haavisto E et al. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics. Psychiatr Serv 1996; 47 (1): 83-85
28. Peacock L, Gerlach J. Clozapine treatment in Denmark: concomitant psychotropic medication and hematologic monitoring in a system with liberal usage practices. J Clin Psychiatry 1994; 55 (2): 44-49
29. Kennedy NB, Procyshyn RM. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2000; 7 (3): 155-159
30. Grohmann R, Rüther E, Sassim N, Schmidt LG. Adverse effects of clozapine. Psychopharmacology (Berl) 1989; 99 Suppl: S101-S104
31. Potter WZ, Ko GN, Zhang LD, Van WW. Clozapine in China: a review and preview of US/PRC collaboration. Psychopharmacology (Berl) 1989; 99 Suppl: S87-S91
32. Shiloh R, Zemishlany Z, Aizenberg D et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569-573
33. Cooke C, Leon J de. Adding other antipsychotics to clozapine. J Clin Psychiatry 1999; 60 (10): 710
34. Allen SA. Effect of chlorpromazine and clozapine on plasma concentrations of haloperidol in a patient with schizophrenia. J Clin Pharmacol 2000; 40 (11): 1296-1297
35. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997; 42 (6): 522-523
36. Stubbs JH, Haw CM, Staley CJ, Mountjoy CQ. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine. Acta Psychiatr Scand 2000; 102 (5): 390-393
37. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11 (3): 313-327
38. Josiassen RC, Joseph A, Kohegyi E et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, doubleblind, placebo-controlled trial. Am J Psychiatry 2005; 162 (1): 130-136
39. Groot IW de, Heck AH, Harten PN van. Addition of risperidone to clozapine therapy in chronically psychotic inpatients. J Clin Psychiatry 2001; 62 (2): 129-130
40. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66 (1): 63-72
41. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004; 37 (1): 26-31
42. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol 2004; 19 (4): 271-273
43. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003; 64 (2): 215-216
44. Tyson SC, Devane CL, Risch SC. Pharmacokinetic interaction between risperidone and clozapine. Am J Psychiatry 1995; 152 (9): 1401-1402
45. McCarthy RH, Terkelsen KG. Risperidone augmentation of clozapine. Pharmacopsychiatry 1995; 28 (2): 61-63
46. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996; 57 (9): 395-397
47. Koreen AR, Lieberman JA, Kronig M, Cooper TB. Cross-tapering clozapine and risperidone. Am J Psychiatry 1995; 152 (11): 1690
48. Godleski LS, Sernyak MJ. Agranulocytosis after addition of risperidone to clozapine treatment. Am J Psychiatry 1996; 153 (5): 735-736
49. Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol 1997; 17 (2): 130-131
50. Patel JK, Salzman C, Green AI, Tsuang MT. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. Am J Psychiatry 1997; 154 (4): 543-546
51. Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry 1998; 10 (3): 113-115
52. Morera AL, Barreiro P, Cano-Munoz JL. Risperidone and clozapine combination for the treatment of refractory schizophrenia. Acta Psychiatr Scand 1999; 99 (4): 305-306
53. Adesanya A, Pantelis C. Adjunctive risperidone treatment in patients with 'clozapine-resistant schizophrenia'. Aust N Z J Psychiatry 2000; 34 (3): 533-534
54. Raju GV, Kumar R, Khanna S. Clozapine-risperidone combination in treatment-resistant schizophrenia. Aust NZJ Psychiatry 2001; 35 (4): 543
55. Raskin S, Katz G, Zislin Z, Knobler HY, Durst R. Clozapine and risperidone: combination/augmentation treatment of refractory schizophrenia: a preliminary observation. Acta Psychiatr Scand 2000; 101 (4): 334-336
56. Rhoads E. Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 2000; 61 (9): 678-680
57. Taylor CG, Flynn SW, Altman S et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001; 48 (1): 155-158
58. Henderson DC, Goff DC, Connolly CE, Borba CP, Hayden D. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001; 62 (8): 605-608
59. Kontaxakis VP, Havaki-Kontaxaki BJ, Stamouli SS, Christodoulou GN. Toxic interaction between risperidone and clozapine: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26 (2): 407-409
60. Raaska K, Raitasuo V, Neuvonen PJ. Therapeutic drug monitoring data: risperidone does not increase serum clozapine concentration. Eur J Clin Pharmacol 2002; 58 (9): 587-591
61. Procyshyn RM, Tse G, Sin O, Flynn S. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol 2002; 12 (1): 77-80
62. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004; 161 (5): 924-925
63. Munro J, Matthiasson P, Osborne S et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004; 110 (4): 292-298
64. Bacher NM, Kaup BA. Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 1996; 153 (1): 137
65. Terao T, Kojima H. Risperidone addition and psychotic exacerbation. J Neuropsychiatry Clin Neurosci 2001; 13 (1): 114-115
66. Potkin SG, Thyrum PT, Alva G et al. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22 (2): 121-130
67. Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001; 46 (1): 86-87
68. Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000; 23 (5): 284-286
69. Seger A, Lamberti JS. Priapism associated with polypharmacy. J Clin Psychiatry 2001; 62 (2): 128
70. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20 (4): 215-219
71. Raskin S, Durst R, Katz G, Zislin J. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000; 20 (5): 500-503
72. Takhar J. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine. J Psychiatry Neurosci 1999; 24 (3): 248-249
73. Jarventausta K, Leinonen E. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 2000; 102 (3): 231-233
74. Mujica R, Weiden P. Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic. Am J Psychiatry 2001; 158 (4): 650-651
75. Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 2002; 36 (3): 437-439
76. Kotler M, Strous RD, Reznik I et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19 (1): 23-26
77. Gomberg RF. Interaction between olanzapine and haloperidol. J Clin Psychopharmacol 1999; 19 (3): 272-273
78. Duggal HS. Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004; 49 (2): 151
79. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses 3. Eur Psychiatry 2004; 19 (1): 56-58
80. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv 2000; 51 (5): 634-638
81. Citrome L, Jaffe A, Levine J, Allingham B. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Psychiatr Serv 2002; 53 (10): 1212
82. Wilson WH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995; 37 (2): 132-133
83. Delva NJ, Letemendia FJ. Lithium treatment in schizophrenia and schizo-affective disorders. BrJ Psychiatry 1982; 141: 387-400
84. Donaldson SR, Gelenberg AJ, Baldessarini RJ. The pharmacologic treatment of schizophrenia: a progress report. Schizophr Bull 1983; 9 (4): 504-527
85. Small JG, Kellams JJ, Milstein V, Moore J. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132 (12): 1315-1317
86. Growe GA, Crayton JW, Klass DB, Evans H, Strizich M. Lithium in chronic schizophrenia. Am J Psychiatry 1979; 136 (4A): 454-455
87. Atre-Vaidya N, Taylor MA. Effectiveness of lithium in schizophrenia: do we really have an answer? J Clin Psychiatry 1989; 50 (5): 170-173
88. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 2003; 23 (3): 223-228
89. Schulz SC, Thompson PA, Jacobs M et al. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. J Clin Psychiatry 1999; 60 (6): 366-372
90. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. Cochrane Database Syst Rev 2003; (3): CD003834
91. Valevski A, Modai I, Lahav M, Weizman A. Clozapine-lithium combined treatment and agranulocytosis. Int Clin Psychopharmacol 1993; 8 (1): 63-65
92. Garcia G, Crismon ML, Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. J Clin Psychopharmacol 1994; 14 (6): 426-428
93. Chen B, Cardasis W. Delirium induced by lithium and risperidone combination. Am J Psychiatry 1996; 153 (9): 1233-1234
94. Peterson GA, Byrd SL. Diabetic ketoacidosis from clozapine and lithium cotreatment. Am J Psychiatry 1996; 153 (5): 737-738
95. Blier P, Slater S, Measham T, Koch M, Wiviott G. Lithium and clozapine-induced neutropenia/agranulocytosis. Int Clin Psychopharmacol 1998; 13 (3): 137-140
96. Durrenberger S, Leon J de. Acute dystonic reaction to lithium and risperidone. J Neuropsychiatry Clin Neurosci 1999; 11 (4): 518-519
97. Owley T, Leventhal B, Cook Jr EH. Risperidone-induced prolonged erections following the addition of lithium. J Child Adolesc Psychopharmacol 2001; 11 (4): 441-442
98. Berry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 2003; 23 (2): 255-259
99. Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents.J Clin Psychiatry 2000; 61 Suppl 14: 33-42
100. Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic patient treated with carbamazepine. Am J Psychiatry 1984; 141 (5): 687-688
101. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2002; (3): CD001258
102. Gerson SL, Lieberman JA, Friedenberg WR et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991; 338 (8761): 262-263
103. Rittmannsberger H, Leblhuber F. Asterixis induced by carbamazepine therapy. Biol Psychiatry 1992; 32 (4): 364-368
104. Rittmannsberger H, Leblhuber F, Sommer R. Asterixis as a side effect of carbamazepine therapy. Klin Wochenschr 1991; 69 (6): 279-281
105. Müller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. Lancet 1988; 2 (8626-8627): 1500
106. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? Pharmacopsychiatry 1993; 26 (6): 262-262
107. Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2004; (1): CD004028-CD004028
108. Casey DE, Daniel DG, Wassef AA et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28 (1): 182-192
109. Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990; 147 (8): 1069-1071
110. Kando JC, Tohen M, Castillo J, Centorrino F. Concurrent use of clozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55 (6): 255-257
111. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J Clin Psychopharmacol 1995; 15 (2): 139-141
112. Wirshing WC, Ames D, Bisheff S et al. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol 1997; 17 (2): 120-121
113. Fisk GG, York SM. The effect of sodium valproate on tardive dyskinesia - revisited. Br J Psychiatry 1987; 150: 542-546
114. Dose M, Hellweg R, Yassouridis A, Theison M, Emrich HM. Combined treatment of schizophrenic psychoses with haloperidol and valproate. Pharmacopsychiatry 1998; 31 (4): 122-125
115. Hesslinger B, Normann C, Langosch JM et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19 (4): 310-315
116. Wassef AA, Dott SG, Harris A et al. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000; 20 (3): 357-361
117. Tiihonen J, Hallikainen T, Ryynanen OP et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003; 54 (11): 1241-1248
118. Kremer I, Vass A, Gorelik I et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56 (6): 441-446
119. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry 2000; 45 (2): 198
120. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry 2002; 63 (11): 1045
121. Navarro V, Pons A, Romero A, Bernardo M. Topiramate for clozapine-induced seizures. Am J Psychiatry 2001; 158 (6): 968-969
122. Baynes D, Mulholland C, Cooper SJ et al. Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment. Schizophr Res 2000; 45 (1-2): 47-56
123. Harrow M, Yonan CA, Sands JR, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20 (2): 327-338
124. Johnson DA. The significance of depression in the prediction of relapse in chronic schizophrenia. BrJ Psychiatry 1988; 152: 320-323
125. Müller MJ, Wetzel H. Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). J Psychiatr Res 1998; 32 (6): 369-378
126. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999; 25 (1): 157-171
127. Wassink TH, Flaum M, Nopoulos P, Andreasen NC. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry 1999; 156 (2): 315-316
128. Zisook S, McAdams LA, KuckJ et al. Depressive symptoms in schizophrenia. Am J Psychiatry 1999; 156 (11): 1736-1743
129. Häfner H. Schizophrenie - von der Tradition zur Gegenwart. Neurotransmitter 2004; (4): 64-68
130. Peuskens J, Baelen B van, Smedt C de, Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 2000; 15 (6): 343-349
131. Tandon R, Jibson MD. Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 2003; 28 Suppl 1: 9-26
132. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55 (3): 250-258
133. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156 (8): 1138-1148
134. Siris SG, Bermanzohn PC, Mason SE, Shuwall MA. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994; 51 (2): 109-115
135. Kirli S, Caliskan M. A comparative study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia. Schizophr Res 1998; 33 (1-2): 103-111
136. Kasckow JW, Mohamed S, Thallasinos A et al. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 2001; 16 (12): 1163-1167
137. Addington D, Addington J, Patten S et al. Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 2002; 22 (1): 20-25
138. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153 (12): 1625-1627
139. Arango C, Kirkpatrick B, Buchanan RW. Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J Nerv Ment Dis 2000; 188 (1): 50-53
140. Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995; 117 (4): 417-423
141. Lee MS, Han CS, You YW, Kim SH. Co-administration of sertraline and haloperidol. Psychiatry Clin Neurosci 1998; 52 Suppl: S193-S198
142. Lee MS, Kim YK, Lee SK, Suh KY. A double-blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia. J Clin Psychopharmacol 1998; 18 (5): 399-403
143. Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. Hum Psychopharmacol 2002; 17 (2): 95-98
144. Salokangas RK, Saarijarvi S, Taiminen T et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94 (3): 175-180
145. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001; 16 (2): 87-92
146. Zoccali R, Muscatello MR, Cedro C et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004; 19 (2): 71-76
147. Anghelescu I, Szegedi A, Schlegel S et al. Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. Eur Neuropsychopharmacol 1998; 8 (4): 315-320
148. Jockers-Scherübl MC, Bauer A, Godemann F et al. Negative symptoms of schizophrenia are improved by the addition of paroxetine to neuroleptics: a double-blind placebo-controlled study. Int Clin Psychopharmacol 2005; 20 (1): 27-31
149. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996; 153 (6): 840-841
150. DuMortier G, Lochu A, Colen DM et al. Elevated clozapine plasma concentrations after fluvoxamine initiation. Am J Psychiatry 1996; 153 (5): 738-739
151. Hiemke C, Weigmann H, Härtter S et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14 (4): 279-281
152. Koponen HJ, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996; 6 (1): 69-71
153. Wetzel H, Anghelescu I, Szegedi A et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18 (1): 2-9
154. Lammers CH, Deuschle M, Weigmann H et al. Coadministration of clozapine and fluvoxamine in psychotic patients - clinical experience. Pharmacopsychiatry 1999; 32 (2): 76-77
155. Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. Adjunctive fluvoxamine inhibits dozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 2004; 65 (6): 766-771
156. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 2001; 7 (3): 283-304
157. Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Int Clin Psychopharmacol 2003; 18 (6): 305-313
158. Szegedi A, Wiesner J, Hiemke C. Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 1995; 15 (2): 141-143
159. Szegedi A, Anghelescu I, Wiesner J et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999; 32 (4): 148-153
160. Kuo FJ, Lane HY, Chang WH. Extrapyramidal symptoms after addition of fluvoxamine to clozapine. J Clin Psychopharmacol 1998; 18 (6): 483-484
161. Olesen OV, Starup G, Linnet K. [Serious drug interaction between clozapine-Leponex and fluvoxamine-Fevarin]. Ugeskr Laeger 1996; 158 (48): 6931-6932
162. Weigmann H, Gerek S, Zeisig A et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23 (4): 410-413
163. Raedler TJ, Jahn H, Arlt J et al. Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry 2004; 19 (6): 366-369
164. Wolkowitz OM. Rational polypharmacy in schizophrenia. Ann Clin Psychiatry 1993; 5 (2): 79-90
165. Arana GW, Ornsteen ML, Kanter F et al. The use of benzodiazepines for psychotic disorders: a literature review and preliminary clinical findings. Psychopharmacol Bull 1986; 22 (1): 77-87
166. Carlsson A, Waters N, Waters S, Carlsson ML. Network interactions in schizophrenia - therapeutic implications. Brain Res Brain Res Rev 2000; 31 (2-3): 342-349
167. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148 (1): 1474-1486
168. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002; 7 (1): 32-43
169. Oepen G. Polypharmacy in Schizophrenia. In: Ghaemi SN (ed.). Polypharmacy in Psychiatry. Dekker, 2002
170. Goff DC, Tsai G, Manoach DS et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996; 153 (12): 1628-1630
171. Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999; 45 (4): 512-514
172. Goff DC, Tsai G, Levitt J et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 1999; 56 (1): 21-27
173. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry 2000; 157 (5): 826-828
174. Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156 (1): 145-147
175. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 2004; 55 (2): 165-171
176. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72 (2-3): 225-234
177. Berlant JL. Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol 1986; 6 (3): 180-184
178. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992; 18 (3): 515-542
179. Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159 (6): 1029-1034
180. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001; 158 (2): 176-184
181. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 2000; 48 (5): 381-388
182. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995: 38 (1): 22-33
183. Friedman JI, Adler DN, Howanitz E et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry 2002; 51 (5): 349-357
184. Fukuzako H, Fukuzako T, Hashiguchi T et al. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 1999; 156 (8): 1205-1208
185. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30 (3): 193-208
186. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25 (3): 463-493
187. Pettegrew JW, Keshavan MS, Panchalingam K et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry 1991; 48 (6): 563-568
188. Stanley JA, Williamson PC, Drost DJ et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res 1994; 13 (3): 209-215
189. Emsley R, Myburgh C, Oosthuizen P, Rensburg SJ van. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159 (9): 1596-1598
190. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49 (3): 243-251
191. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158 (12): 2071-2074
192. Strous RD, Maayan R, Lapidus R et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry 2003; 60 (2): 133-141
193. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50 (9): 322-328
194. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42 (4): 233-246
195. Beasley Jr CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14 (2): 111-123
196. Marder SR. Risperidone: clinical development: north American results. Clin Neuropharmacol 1992; 15 Suppl 1 PtA: 92A-93A
197. Marder SR, Glynn SM, Wirshing WC et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 2003; 160 (8): 1405-1412
198. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002; 56 (1-2): 1-10
199. Bitter I, Dossenbach MR, Brook S et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28 (1): 173-180
200. Conley RR, Tamminga CA, Bartko JJ et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155 (7): 914-920
201. Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter Jr WT. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 2003; 23 (6): 668-671
202. Lindenmayer JP, Iskander A, Park M et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 1998; 59 (10): 521-527
203. Bondolfi G, Dufour H, Patris M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998; 155 (4): 499-504
204. Sacchetti E, Panariello A, Regini C, Valsecchi P. Quetiapine in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr Res 2004; 69 (2-3): 325-331
205. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 2000; 26 (1): 119-136
206. Bilder RM, Goldman RS, Volavka J et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159 (6): 1018-1028
207. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159 (1): 103-108
208. Strasser O, Schmauss M, Messer T. Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication. Psychiatr Prax 2004; 31 Suppl 1: S38-S40
209. Kilian R, Dietrich S, Toumi M, Angermeyer MC. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatr Scand 2004; 110 (2): 108-118
210. Hertling I, Philipp M, Dvorak A et al. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology 2003; 47 (1): 37-46
211. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162 (1): 3-10
212. Ritsner M, Gibel A, Perelroyzen G et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004; 24 (6): 582-591
213. Voruganti L, Cortese L, Oyewumi L et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43 (2-3): 135-145
214. Voruganti L, Cortese L, Owyeumi L et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57 (2-3): 201-208
215. Hovens JE, Dries PJ, Melman CT, Wapenaar RJ, Loonen AJ. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. J Psychopharmacol 2005; 19 (1): 51-57
216. Lejeune J, Larmo I, Chrzanowski W et al. Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis. Int Clin Psychopharmacol 2004; 19 (5): 259-269
217. Zarate Jr CA, Daniel DG, Kinon BJ et al. Algorithms for the treatment of schizophrenia. Psychopharmacol Bull 1995; 31 (3): 461-467
218. Centorrino F, Goren JL, Hennen J et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004; 161 (4): 700-706
219. Janssen B, Weinmann S, Berger M, Gaebel W. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004; 30 (4): 1023-1033
220. Miller AL, Crismon ML, Rush AJ et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004; 30 (3): 627-647
221. Szegedi A, Anghelescu l, Wiesner J et al. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 1999; 32 (4): 148-153
222. Lammers CH, Deuschle M, Weigmann H et al. Coadministration of clozapine and fluvoxamine in psychotic patients - clinical experience. Pharmacopsychiatry 1999; 32 (2): 76-77
223. Hiemke C, Weigmann H, Härtter S et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14 (4): 279-281